Member Info for crumbs

Jeez shes a fast worker!!... my advice there is 'yes dear once scancell get to a quid' :))
Great to hear you were not tortured in vain though and hopefully, you will fully benefit from it, your constant punching has paid off so keep at it!

Proactive it also sounded to me scancell had decided on the nano delivery for SCIB2 and it was now all about getting CRUK to license it... sounded positive on that too... so expect that bit of important news too... SCIB2 in a trial by next year as well!

I'm not expecting director buys I'm expecting at least BioNtech deal and at most that and a modi1 one too.... watch this space... talks have been going on around the moditope platform with third parties since... 2013!!!

Twitter clues... RG has now tweeted the latest BioNtech deal
https://twitter.com/BioNTech_Group/status/1126158440244625408
He also retweeted John Glencross's tweet about SCIB1 going into trial... with 2 more trials next year!

All very encouraging I would say as at this stage of our BioNtech collab ... they surely know what is coming!

You might not be able to keep TCR out of the equation soon :)

I agree the appointments RNS was pivotal, scancell really needed those guys and they got them! Two top class capable experts in their fields... just like this CAB... I do not think there are many tiny biotechs that can attract such esteemed in their fields people to get involved are there :)
Yes for me the most exciting thing is that the trial looks set to be one of the most potentially game-changing trials in oncology history.. they are not sticking to one target they are open to going for all potential responders and that is a lot of potential!!... a trial that alone could transform into the IO field leader (mcap of £15 million lol).. but certainly one that ought to give a full understanding of how moditope performs in human patients...

Constant updates can be a bad thing... getting moditope to the clinic has not been plain sailing... this latest RNS reveals that... tox testing began in April... what!! I thought it began last year hmm... the manufacturing we thought that had began too but no and now this Glasgow firm needed.... the reasons will be nothing like modi1 has ever been made before it is a totally new form of peptide therapeutic with the AMPLIVANT adjuvant combined ... it has obviously not been easy for team scancell science to get it to be a clinically ready product hence the bringing in of Adrian..top move!... same as with Sam for TCRs... this CAB has only been created as now moditope is at last 'ready'... I'm pretty sure some on that CAB have been giving advice already Ottenmeiser was a project blueprint member and head and neck as a priority target came from project blueprint work ( CRUK kindly gave it 30k) ....As to BioNtech deal and sp.. I don't know as they are working like that.. it is a research collab with an ending and potential deal.. so it has to be all about what is happening in the labs and are they happy... if they are the deal will happen if not then either it gets an extension or it's handshakes and goodbye or a we like what you have but this is not working out so lets try something different situation ... we will see, however their US purchase (we have no idea did they get a bargain) shows they are willing to be mercenary in their ambitions as that company was desperate for a buyer and looked set to merge with another company before BioNtech jumped in it obviously fits in with BioNtechs bigger plans of getting a US foothold. .... could hopefully be plenty of newsflow here now and moditope has never ever been more deal ready... patented and trial ready...multiple solid tumour targets.

With close ties to the NHS and NICE and the CRUK too... what could go right!

modi1 trial potential targets from investor day way back in 2013... this list is already longer as sarcomas were later added ...

Potential for treating any tumour expressing modified peptides
From antibody studies, vimentin expressed in all of the following tumour types:
Breast
Prostate
Ovarian
Cervical
Endometrial
Head and neck
Thyroid
Glioma
Lung
Melanoma
Skin
Testis
Urothelial
Renal
Stomach
Pancreatic
Liver

Imagine the modi1 trial expands to cover late-stage patients who basically have no more options in many if not all of those targets.....
3 days after one therapeutic dose of modi1 humanised mouse models with the biggest ethically allowable tumour burdens become cancer free as those tumours dissolve due to a cytotoxic killer CD4 t cell attack.... and that is in 100% of the animals.....
potentially the most exciting and game-changing IO trial ever... I think so... any maybe just maybe some others with vested interests and deep pockets thinks to too :)

Yes this CAB news is exciting it means the modi1 trial may develop into something far more than a 3 target trial.... Cliff already told me sarcomas could still make an appearance once the trial is underway and got to a stage where modi1 is proven safe and effective... sounds to me many more solid tumour targets could appear too... possibly 18 targets even!!! Now that would be expensive but if modi1 is working the rewards would be massive... it sounds to me there are talks around a modi1 deal (multiple talks from OO RNS and what Cliff said at proactive event about potential modi1 deal) so not a whole moditope platform deal... makes sense for scancell that as modi2 becomes a whole lot more valuable if modi1 proves the science behind the platform.... modi1 is now at a stage to make it a very attractive deal proposition to oooh what at least 20 odd pharmas and big biotechs that have,need and want IO assets...This CAB will only help sell it as will the manufacturing niggles being overcome no doubt new guy Adrian has made a big contribution already there... tox testing has now begun ( seems later than we thought) but finished by H2... this means though Q1 2020 is the pencilled in trial date....it could with the right circumstances possibly begin once those tox tests are complete.... all very exciting

lol knowlesi has no special powers all LTH know the same until funding is sorted the trend is downwards I've said it many times the other truth which he struggles with though is he can never ever predict what the next RNS will say... if he could he would have traded and made himself a fair few quids out of scancell this week wouldn't he... but he didn't... does he know when the BioNtech deal may drop? no... he likes to say they are waiting for modi1 trial results but that is not what the collab RNS says it says once the collab is finished... well it finishes soon- June... so time that one! Time further SCIB1 news time SCIB2 news (CRUK licensing nano delivery -all systems go) time modi1 progress and very possible modi1 deal (that would be massive) time modi2 news ( TCR collab too?) time Glycan MaBs action ( potential deals) time something out of the blue! (project blueprint still has life- hello Genentech) ...time a surprise from China... no he cannot the only way you time those things is by being in... I'm in I'm under the water that does not make me happy but that so much newsflow can come here and that scancell actually have investment attractive assets means I'm ok with it...that moditope is going into trial that that trial may start with 3 targets in 60 patients but end in many many more solid tumour targets in many more desperate need patients is very very exciting indeed ... potential total game changer!... Everyone here would have loved to have been in on Checkpoint inhibitor tech in its early days seeing as now they command a multi $billion market... well they had a bumpy ride getting to that... moditope could blow them away and CAR T valuations too.... risk / reward... well as you say it is going to be all about the science in the end... and moditope is going into trial!... you would think not only clinicians are interested in that fact :)

Correct however it is not as if there is nothing worth financing as also in the real world cancer kills daily and scancell just might have part of the answer and possibly a very big part to making that a thing of the past .... and it is not just 'desperate pi' saying that as todays RNS and others are testaments... moditope is here as a clinically ready product and all patent protected too :)

To see Christian Ottensmeier involved in the modi1 trial plans.... and where is he the week after next
http://www.meeting.cimt.eu/speakers
Alongside none other than our other good friend Ugur Sahin...small world and all that...

Well always used to think the same about the SCIB1 combo trial when they got KF on board to run the trial stateside we were wrong about that though lol even though it did get funded eventually it was by a market raising... and still we await that US arm... however I think it is on its way...

Modi1 is something else though and the way the trial seems to be open to expanding beyond 3 targets once the mechanism is showing itself to be effective means that trial could become the most exciting trial in all IO history... it could be a complete game changer in oncology treatment in multiple late-stage solid tumour cancers.... massive!... And with modi2 coming up behind it would place scancell in an amazing position... often times we get what are the BOD going to do about the sp fall... well today they did something they really did not need to release this news however in doing so they are showing just how much is going on and how modi1 is now a very attractive deal proposition indeed... plenty more newsflow to come... TCRs modi1 modi2 Scib1 Scib2 and glycan Mabs.... and who knows what else from the poundland BioNtech... a good time to get in I think ...if only I knew that a million years ago :)

The targets are 'including' if modi1 is showing positive.effect in the initial 3 targets expect the trial to be expanded into many more targets up to 17 intact ....Massive and exciting

Of course, all kinds of possibilities seeing as how BioNtech by now one would think have a real insight into moditope like no one else outside of scancell in as much as they have been working intimately with scancell team science to use modi1 to create cancer targeting TCR therapies... however the original idea is a simple licensing deal:

'Under the terms of the agreement, Scancell and BioNTech will enter into an initial research collaboration to discover and characterise T cell receptors specific for citrullinated epitopes from vimentin and enolase. These epitopes form the basis of Scancell's first Moditope® development candidate, Modi-1. Upon completion of these studies, BioNTech will have the exclusive option to enter into a licence agreement for the development of cell receptor based therapeutics that are specific to Modi-1 epitopes.'

Such a deal in this area you would expect at least $10 million upfront plus milestones... this would be an advanced program with clinical possiblities in the near term due to such a long pre clinical collab... meaning milestones could get triggered fast....

If they now also want to include modi2 which indeed could be the case... scancell will be in a very nice position on licensing deals on both.... and such upfront monies would be totally transformational considering current mcap situation... of course BioNtech knowing the potential of moditope could well be fishing for a much better tie up for them where they gain moditope IP ... don't think scancell are behind the door here though... scancells pipeline value could well totally eclipse BioNtechs in a few short years... think about that :)

I'd suggest the further tie up with BioNtech could simply be....modi2.... I believe they have probably been looking at that already in the lab... their 'deal' with scancell though is solely modi1....any tie up if they do it around modi2 would be a great big flashing light that they are happy with modi1 and the whole moditope approach...we'll see

Yes you get the feeling things with BioNtech must be going well simply as they have been working with moditope for over a year now... this means they are seeing its potential and just like the Karolinska they are not dropping it but possibly broadening their collaboration... it will come good here value will come simply because the moditope platform is already in others hands others who also have money in pocket... BioNtech, karolinska and especially Genentech... project blueprint I've been told is not a dead project

yeah probably.... at the moment it is bearish :)

BioNtech are waiting on collab results... now yes you would think they know a lot already and yes would know is this something they want to be a part of... we do not know- yet... an encouraging thing from proactive with that in the post-presentation chit chat (which you hold a lot of value to) CH is said to have indicated there may well be further projects with BioNtech... what can that mean!!?.... but really unless both parties are getting those TCRs that will go into trials there will be no TCR deal... interestingly BioNtech have over the months been recruiting staff mostly around their mRNA program but also their gene therapy program which of course includes TCR so must have clinical plans... do they include using moditope? we as of yet do not know.... we do know there is also a potential modi1 deal on cards.. and we know now that head and neck replaced sarcomas as a modi1 target due to project blueprint work ... plenty going on lets hope near to baring some real fruits for shareholders as that is very long overdue here.

So true, the problem is keeping those ducks afloat... no desperate need just yet and you would really think they will know how close a deal of either TCR BionTech form or someone coming in on modi1 is... no fundraising despite them being aware of this CF situation... only time will tell if those ducks get the chance to fly and with it the sp

'fundamentals intact' I think is the catchy phrase